Ekf Diagnostics Share Discussion Threads

[ppmm] 09/6/2021 13:08

I have every confidence that the trading statement will confirm the confidence and excitement regarding prospects that I read in from the directors. A question I have though if the announcement can contain at this stage the categoric confirmations that the market seems to crave. Time will tell.

[faz] 09/6/2021 11:29

charlie - ok well I clearly reported that wrong from the AGM. NEver mind

[tongosti] 09/6/2021 07:31

Maybe - let's see what today will bring.

[davr0s] 08/6/2021 20:16

Ignore it - UTs are highly unpredictable. It will highly likely open within a tad of the closing bid offer

[tongosti] 08/6/2021 19:55

Wow closing at the day's low. As they say patience is a virtue.

[charlieej] 08/6/2021 17:59

FazPost 1920You said.."Trading update wc 7 June and a roadshow same week."That was on the day of the AGM if I'm not mistaken. Strange

[faz] 08/6/2021 16:43

Charlie: I havent said there would be a trading update. I wrote(post 2038) that JBaines mentioned at the AGM that a roadshow would take place around 10 June. And that is indeed happening this week. The slide presentation to be used is on the EKF website.

[charlieej] 08/6/2021 15:47

Faz... you previously stated trading update this week. Can you confirm that was what was mentioned at the AGM? Or anyone else?

[tongosti] 08/6/2021 13:28

Happy to bide my time and carry on waiting. If this is supposed to go North, Mr Market has to approve it. Until then ...

[rivaldo] 07/6/2021 11:52

Today's RNS for the record - good to see management out there spreading the word:



"EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that Julian Baines and Mike Salter (who will become Chief Executive Officer on 1 October 2021) will be presenting to institutional investors this week following the recent AGM statement which set out the Company's strategy for growth through to 2024."

[mirandaj] 05/6/2021 07:35

Thank you wan.

[wan] 05/6/2021 06:38

I thought that yesterdays MyHealthChecked Results made for a very interesting read. In particular, the commentary regarding COVID-19 testing, and the larger opportunity going forward presented by in-home testing beyond COVID-19, which is set to evolve and grow rapidly and is on track to reach $16bn in 2027 -


Having the reassurance in the reliability of 'laboratory' accurate results from home tests will no doubt play a very important part (and it's almost certainly why Amazon's testing ambitions also involves laboratories).

Make no bones about it, the pandemic has raised the profile and transformed the face of diagnostics, with the next few years likely to represent a huge growth opportunity and a relative revolution in diagnostics!

For an excellent weekend read -

The revolution in DIY testing that will outlive the pandemic

The rapid development of diagnostics for Covid-19 should help stay on top of fresh outbreaks and flu when it re-emerges

Anna Gross in London JUNE 3 2021

While the huge public expenditure — around £19bn has been spent on all forms of Covid-19 testing so far in England alone — cannot continue, a system will be needed to quickly catch fresh outbreaks and to identify new variants. There is also huge demand for tools that can distinguish between Covid, flu and a common cold — so that a winter sniffle does not lead to a period of enforced self-isolation.

Full story FT.com -

[tongosti] 03/6/2021 13:18

This is what one likes. Good relative strength in the face of a falling wider market. Still out (for the record) but watching closely.

[faz] 03/6/2021 11:26

JBaines mentioned at the AGM that a roadshow would take place around 10 June. Any details anyone: an investor meet company pres, a capital day for institutions?

[faz] 03/6/2021 10:50

cheers Don! or Prof if you are don :}

[wan] 03/6/2021 09:16

To perhaps put into better context why we should be careful what we read into the above article, the following excerpt from the AGM Statement and Growth Plan 2024, is perhaps instructive, especially with regard to the contract length, and importantly the prospect of a much broader commercial testing capacity to cover other areas of infectious disease, chronic disease and general health and wellness -

5. Driving value from our COVID-19 business and evolve our contract manufacturing capabilities

As I’ve mentioned above we do not believe our COVID-19 business will end suddenly. Our largest contract is for a minimum of two years and as we continue to win new clients we are investing further in our manufacturing capacity to meet the increasing demands of our clients. However, we know that we also have the opportunity to leverage this capability in test-kit contract manufacturing created across our sites in the US, UK and Europe to provide other services. We are already in discussions with our private sector partner, with whom we have a recently signed, multi-million dollar global supply contract, regarding the expansion of our support beyond their world-wide COVID-19 testing programme for their staff, to supporting a much broader commercial testing capacity to cover other areas of infectious disease, chronic disease and general health and wellness.

Our manufacturing capabilities are applicable in other areas of diagnostic testing, and for molecular disease and forensic test manufacture. We are also evaluating the potential to offer contract development services, whereby we would use our existing skills to support customers earlier in the process of product development and specification.
hxxps://www.ekfdiagnostics.com/agm-statement1.html

Fwiw, I find the above paragraphs reassuring, exciting and very intriguing!

[cambridgedon] 03/6/2021 09:13

For Faz and others.
No! That would be too much to hope for. I only found out what I did by calling Dealing and asking. Apparently, the balance of the cash may not come back for "5-10 days."
CD

[wan] 03/6/2021 08:53

In my view, we should be aware, but also be careful how much to read into the following article regarding Abbotts downgrade to earnings from, and in particular, the faster than expected decline in 'rapid' COVID-19 testing demand -

Abbott's COVID-19 testing surprise suggests demand softening faster than sector forecast
Published June 2, 2021

Abbott CEO Robert Ford told investors Tuesday it had no way of knowing in April when it reported first-quarter earnings that market dynamics would change so dramatically in subsequent weeks. At that time, Ford said Abbott was seeing coronavirus case rates holding steady in the U.S. and other major developed countries. However, in May, the test maker experienced a "sudden" and fundamental drop-off in demand for COVID-19 testing, particularly for screening and surveillance with rapid testing.

"While we've always said the demand for COVID testing sales would eventually work its way to a flu-like level, we couldn't have anticipated what has occurred over the past several weeks," Ford told investors on Tuesday's conference call.

Abbott now forecasts about $4 billion to $4.5 billion in COVID-19 testing sales in 2021, including second-quarter sales of around $1.1 billion. The company previously forecasted about $6.5 billion to $7 billion in coronavirus test sales on its fourth-quarter earnings call in late January.

Looking beyond 2021, SVB Leerink analysts Tuesday wrote that "given that the new guidelines might eliminate the end-user demand effectively" they slashed their 2022 Abbott COVID-19 testing revenue estimate of about $3.5 billion to $4 billion to approximately $300 million.

Jefferies analysts also now forecast $300 million of overall COVID-19 testing in 2022 based on their assumption of a "faster drop to a normal-like seasonal flu trend."

News of the plummet in test demand and the company’s decision to cut its 2021 outlook sent Abbott's stock down more than 9% yesterday, while Quidel's share price dropped more than 7% in reaction.

Full story -

Rapid testing of the type Abbott is particularly referring to is not related to PCR testing, and such rapid testing is not dependant on a specimen collection device e.g. such as that used in test kits, pooled samples and sequencing etc, which EKF manufacture and supply.

[faz] 03/6/2021 08:17

cambridgedon, have they updated your portfolio? I've heard nothing from them

[wan] 03/6/2021 05:04

Following on from post 2025 -

Amazon beefs up Covid testing capabilities
Published4 hours ago

Amazon is to expand its Covid testing lab facilities in the UK as the pandemic continues.

The online giant said this was to benefit employees and UK public health.

However, analysts said it could also provide business opportunities in the health sector and buff up Amazon's reputation after questions over working conditions.

Amazon recently moved into the online pharmacy business in the US for subscribers to its Prime service.

Lab tests
In 2020, the online retailing giant set up laboratories in Kentucky and in Greater Manchester to process employees' PCR tests.

The lab in Manchester has processed 900,000 test samples to date.

The test results are anonymous and will be shared with Public Health England once the lab is approved for sequencing.

Its coronavirus response efforts have so far cost the company $11.5bn (£8.1bn).

Tom Forte, managing director and senior research analyst at D.A. Davidson, said Amazon could convert staff Covid-19 testing and healthcare clinics for consumer use.

"We believe Covid-19 inspired Amazon to accelerate its healthcare-related efforts, by necessity.

"That said, we had long believed healthcare was an attractive opportunity for Amazon given its large market size and chances for the company to both improve the customer experience and lower the costs."

There are very few companies in the world who could have decided to build a state of the art diagnostics lab and have it functioning within months, but Amazon is one of them.

While the company insists that at the moment this site is purely to help keep their staff safer at work, they are sending out a very clear message.

They are able to process medical diagnostics and feed that information into public health agencies.

Right now this multimillion-pound site in Salford is only testing for Covid-19, but it's unlikely to be left idle after the pandemic.

Full story -

[cambridgedon] 02/6/2021 14:31

A J Bell just confirmed scale-back for TRLS IPO at 6.4%
CD

[mg1982] 02/6/2021 11:49

true, you've got a track record of providing accurate entry and exit prices along with % gains

[tongosti] 02/6/2021 11:46

Don't worry darling. Like I always do on this board I always give on the day when I enter and exit. Stay tuned mr politeness.